10-year follow-up of a phase 3 trial in 1200 men with intermediate- or high-risk localised prostate cancer: ultra-hypofractionated radiotherapy (7 fractions) stayed non-inferior to conventional (39 fractions); failure-free survival 72% vs 65% (HR 0.84), similar late toxicity.
RCTn = 1,200
Nilsson et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial